Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 3
Cost-effectiveness analysis for trigeminal neuralgia: Cyberknife vs microvascular decompression
Authors Tarricone R, Aguzzi G, Musi F, Fariselli L, Casasco
Published 6 June 2008 Volume 2008:4(3) Pages 647—652
Rosanna Tarricone1, Giovanni Aguzzi1, Francesco Musi1, Laura Fariselli2, Andrea Casasco3
1Economic Evaluation Area, CERGAS Centre for Research on Healthcare Management-Bocconi University, Milan, Italy; 2Radiotherapy Department, Carlo Besta National Neurological Institute, Milan, Italy; 3Centro Diagnostico Italiano, Milan, Italy
Background/Aims: We present the preliminary results of a cost-effectiveness analysis of cyberknife radiosurgery (CKR) versus microvascular decompression (MVD) for patients with medically unresponsive trigeminal neuralgia.
Methods: Direct healthcare costs from hospital’s perspective attributable to CKR and MVD were collected. Pain level caused by trigeminal neuralgia was measured through the Barrow Neurological Institute pain intensity scoring criteria, at admission and after an average of 6 months follow-up.
Results: 20 patients for both arms were enrolled, for a total of 40 patients. The two procedures resulted equally effective at 6 month follow-up, with different resources consumption: CKR reducing hospital costs by an average of 34% per patient. The robustness of these results was confirmed in appropriate sensitivity analyses.
Conclusion: CKR resulted to be a cost-saving alternative compared with the surgical intervention.
Keywords: decision-making, cost-effectiveness analysis, Cyberknife, microvascular decompression, trigeminal neuralgia
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.